MedPath

Remind Adolescents and Young Adults; REMIND-AYA

Phase 3
Not yet recruiting
Conditions
HIV/AIDS
Registration Number
PACTR202303867267716
Lead Sponsor
Kilimanjaro Clinical Research Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
240
Inclusion Criteria

Participants must be on first line ART regimen (Tenofovir/Lamuvidine/Dolutegravir) or (Tenofovir/Lamuvidine/Efavirenz)
Participants must have had full disclosure of their HIV status
Participants must be able to read and understand Chichewa or English
Participants must be competent in the use of mobile devices.

Exclusion Criteria

Hospitalisation at the time of study entry
Prior participation in digital adherence health research
Enrolment in other HIV-related studies
Treatment for a comorbidity that significantly increases the participants’ pill burden.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.